The FDA is requiring makers of GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to warn patients and clinicians about a possible risk of NAION, a rare condition caused by reduced blood flow to the optic nerve.
Novo Nordisk A/S and Eli Lilly & Co. must warn weight-loss drug users of a possible rare side effect that could affect their vision, following a new requirement from the Food and Drug Administration.
The FDA today informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.
WASHINGTON (AP) — Popular weight loss drugs including Ozempic and Wegovy will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators announced Monday.
The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.
The eye condition, known as non-arteritic anterior ischemic optic neuropathy, has been reported with all GLP-1 drugs. It can lead to significant vision loss.
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.
The U.S. Food and Drug Administration (FDA) is mandating new safety labels for popular diabetes and weight-loss medications following investigations into a rare eye condition. According to a November 2026 safety communication, medications in the GLP-1 class carry a potentially increased risk for non…
The Food and Drug Administation (FDA) will require drugs like Ozempic, Wegovy and Zepbound to carry a warning label about the risk of a rare condition known as "eye stroke."
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent …
The FDA is adding a new warning label onto GLP-1 drugs like Ozempic and Zepbound for a rare side effect with serious risk. All GLP-1 drug makers will now be required to include new safety warnings informing patients that the medications could increase risk of sudden vision loss from a condition know…
FDA is now requiring GLP-1 weight-loss drugs to include warning information about the rare potential for vision loss. The mandate follows a review of available research and patient complaints, but the FDA did not find a direct cause-and-effect relationship between GLP-1s and vision loss.
The U.S. Food and Drug Administration (FDA) is requiring makers of Ozempic, Wegovy and similar drugs to warn of a rare eye condition that can cause vision loss.
The Food and Drug Administration is requiring new warnings on GLP-1 drugs, including Ozempic, Wegovy and Zepbound, about a potential increased risk of a rare eye condition that can cause permanent vision loss.
by Hanna Heller at CDN - The FDA is requiring every GLP-1 weight-loss and diabetes drug to warn of a rare eye condition that can cause sudden, permanent vision loss in one eye. Here are the symptoms to watch for.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Related updates
Separate coverage close to this update in time and subject.
